Platinib for the treatment of lung cancer: What factors are related to the duration of treatment?

Pralsetinib, also known as BLU-667, is a potent and highly selective RET kinase inhibitor that has shown significant therapeutic efficacy in tumors with oncogenic RET mutations. Whether in vitro experiments or in vivo models, platinib exhibits inhibitory effects on a variety of RET mutations, including KIF5B-RET, CCDC6-RET fusions, and mutations such as RET M918T, RET C634W, RET V804E, RET V804L, and RET V804M.

In the pivotal study calledARROW, 87 patients with RET fusion-positive non-small cell lung cancer who had previously received platinum-based chemotherapy were treated with platinib at a dose of 400 mg daily. After a median follow-up of 17.1 months, the overall response rate (ORR) of these patients reached 61%, and the median progression-free survival (PFS) was as long as 17.1 months. In the 27 untreated patients, the ORR was 19% and the median PFS was 9.1 months. These data not only prove the efficacy of platinib in non-small cell lung cancer, but also provide an important reference for doctors to formulate treatment plans.

However, the treatment duration of platinib is not static and is affected by many factors. First, the patient's overall health and tolerance are key factors. If the patient is in good health and able to tolerate platinib treatment, the course of treatment may be relatively long. Conversely, if a patient experiences severe side effects or is unable to tolerate the drug, doctors may adjust the treatment plan, including reducing the dose, suspending treatment, or even discontinuing treatment.

In addition, treatment goals are also one of the important factors in determining the length of treatment. For some patients, the primary treatment goals may be to relieve symptoms, improve quality of life, or prolong survival. For other patients, more emphasis may be placed on long-term control of the disease or prevention of recurrence. Therefore, doctors will develop a personalized treatment plan based on the patient's specific situation and treatment goals. In short, the length of treatment course for platinib in the treatment of lung cancer is a complex issue that requires comprehensive consideration of multiple factors. By closely monitoring the patient's response and tolerance, and through thorough communication and discussion with the physician, a personalized treatment plan can be developed that best suits the patient.